Decoding how Korean beauty becomes global business.

Comments on two Korean cosmetics notices closed on 18 September 2026, and the coverage has been about price: an SPF test that takes about a month and costs about six million won drops to about two days and about 3.5 million. Buried in the same package is the clause that moves more money. It narrows the waiver that lets a second, third and twelfth brand ride an already-approved sunscreen dossier without running a test at all. The test gets cheaper. The number of products that

Korea gates commercial cosmetics imports through a registrant. An importer registers as a responsible distributor under Article 3 of the Cosmetics Act, files a clearance report before customs release, and tests each batch before sale. On 17 September two agencies announced that roughly 97,000 counterfeit units had moved through Coupang and Naver over fourteen months. None of those controls failed. None of them applied.

Hyundai Department Store opens Khōde, a 165 square metre derma beauty shop, on the basement floor of its Pangyo store on 18 September 2026, with around 60 brands and some 250 products aimed at shoppers in their thirties and forties. Olive Young is not absent from this category. It put an Advanced Derma section into 650 of its stores within four months of launching it in March 2026. The category is not what separates them. The format is.

Korea founded the Global Cosmetics Regulatory Authority Summit (GCORAS) to lead regulatory alignment across key export markets like ASEAN, the Middle East, and Latin America. Paired with Korea’s mandatory Safety Assessment regime phasing in from 2028, GCORAS aims to establish mutual recognition for safety dossiers. This turns a domestic compliance burden into a portable global export asset, mitigating fixed compliance costs for indie brands while expanding ODM service roles.

K-Beauty clinical trials have devolved into a profit-driven circus where testing labs unbundle basic device metrics to inflate fees, while subject recycling and data manipulation threaten scientific validity. Domestic brands overspend on superficial device scores, whereas fast-growing brands opt for cost-effective user surveys. Overseas, lax clinical data poses catastrophic legal risks under post-market compliance systems like MoCRA (US) and CPNP (Europe).